FDA approve of Vyxeos (daunorubicin and cytarabine) for the secondary Acute Myeloid Leukemia in paediatric patients

Newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in paediatric patients aged one year and older is now approved in the US, on the basis of data from two single-arm trials: AAML1421 and CPX-MA-1201.

Source:

Biospace Inc.